Cyclerion Therapeutics (CYCN) Announces CY6463 Pipeline Progress; Reports Q2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Cyclerion Therapeutics (CYCN) Announces CY6463 Pipeline Progress; Reports Q2

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

August 9, 2022 4:00 PM EDT

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS)

Study in Alzheimers Disease with vascular pathology (ADv) enrollment ongoing

Appointed Steven E. Hyman, M.D. to its Board of Directors

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022... More